CLINICAL_TRIALS
trial_result
· 2026-03-31
Clinical Trial Update: Spesolimab in Pyoderma Gangrenosum [Phase 2]
Summary
A Phase 2 trial evaluating Spesolimab for Pyoderma Gangrenosum was terminated, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Pyoderma Gangrenosum | Phase 2 | Status: TERMINATED | Results posted: 2026-03-31